Home > Partners > GALAPAGOS

Premium Plus partner


Galapagos is a fully-integrated biotechnology company with a European commercial footprint and headquarters in Mechelen, Belgium.  We discover, develop and commercialize small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications.

We focus on the development of first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers which proteins (‘targets’) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease rather than just treating the symptoms.

Galapagos' mission is 'Pioneering for patients'. In all our activities, we want to make a difference for patients, their caretakers and loved ones. Our ambition is to improve patients' lives and make a lasting positive contribution to society through science and partnerships.



Visit website